Beximco Pharmagdr Regs Stock Cash Per Share
| R2WA Stock | EUR 0.41 0.00 0.00% |
BEXIMCO PHARMAGDR REGS fundamentals help investors to digest information that contributes to BEXIMCO PHARMAGDR's financial success or failures. It also enables traders to predict the movement of BEXIMCO Stock. The fundamental analysis module provides a way to measure BEXIMCO PHARMAGDR's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to BEXIMCO PHARMAGDR stock.
BEXIMCO |
BEXIMCO PHARMAGDR REGS Company Cash Per Share Analysis
BEXIMCO PHARMAGDR's Cash per Share is a ratio of current cash on hands or in the banks of the company to a total number of shares outstanding. It is used to determine a firm's liquidity and is a good indicator of the overall financial health of a company. Value investors often compare this ratio to the current stock quote, and if it exceeds the stock price they would invest in it.
Companies with high Cash per Share ratio will be considered as an attractive investment by most investors. In most industries if you can single out an equity instrument trading below its cash per share value, you have a bargain and should consider buying it. Finding the stocks traded below their cash value, therefore, can be a good starting point for investors using strategies based on fundamentals.
| Competition |
In accordance with the recently published financial statements, BEXIMCO PHARMAGDR REGS has a Cash Per Share of 0.0 times. This is 100.0% lower than that of the Healthcare sector and about the same as Drug Manufacturers-Specialty & Generic (which currently averages 0.0) industry. The cash per share for all Germany stocks is 100.0% higher than that of the company.
Did you try this?
Run Portfolio Rebalancing Now
Portfolio RebalancingAnalyze risk-adjusted returns against different time horizons to find asset-allocation targets |
| All Next | Launch Module |
BEXIMCO Fundamentals
| Return On Equity | 0.12 | |||
| Return On Asset | 0.0659 | |||
| Profit Margin | 0.14 % | |||
| Shares Outstanding | 446.11 M | |||
| Shares Owned By Institutions | 2.09 % | |||
| Gross Profit | 15.71 B | |||
| Debt To Equity | 27.50 % | |||
| Current Ratio | 2.26 X | |||
| Earnings Per Share | 0.10 X | |||
| Number Of Employees | 5.5 K | |||
| Beta | 0.8 | |||
| Market Capitalization | 563.15 M | |||
| Annual Yield | 0.06 % |
About BEXIMCO PHARMAGDR Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze BEXIMCO PHARMAGDR REGS's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of BEXIMCO PHARMAGDR using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of BEXIMCO PHARMAGDR REGS based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
Other Information on Investing in BEXIMCO Stock
BEXIMCO PHARMAGDR financial ratios help investors to determine whether BEXIMCO Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in BEXIMCO with respect to the benefits of owning BEXIMCO PHARMAGDR security.